본문 바로가기
KERD
논문KCI 등재

Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance

이명진|구현경|강형구|강지은|Song Je Eun|곽이경|Kang Jiyeon|Park Hye Kyeong|Choi Sang Bong|Lee Hyuk Pyo|Kim Baek-Nam
대한감염학회 (The Korean Society Of Infectious Diseases)|2022.12|Infection and Chemotherapy|제54권 제4호|pp. 781-786|DOI 10.3947/ic.2022.0103

1

조회

0

다운로드

2

인용

0

참고문헌

키워드

COVID-19RegdanvimabDelta variant
주제분류내과학

초록

Regdanvimab is the only monoclonal antibody available in Korea that targets severe acute respiratory syndrome coronavirus 2. We retrospectively evaluated the clinical characteristics of 374 adults hospitalized with coronavirus disease 2019 (COVID-19) who were treated with regdanvimab from September through December 2021. In total, 322 (86.1%) patients exhibited risk factors for disease progression. Most patients (91.4%) improved without additional treatment. No patient died or was transferred to intensive care. This study shows that regdanvimab prevented disease progression in high-risk patients with mild to moderate COVID-19 infections during Delta variant predominance.

Abstract

Regdanvimab is the only monoclonal antibody available in Korea that targets severe acute respiratory syndrome coronavirus 2. We retrospectively evaluated the clinical characteristics of 374 adults hospitalized with coronavirus disease 2019 (COVID-19) who were treated with regdanvimab from September through December 2021. In total, 322 (86.1%) patients exhibited risk factors for disease progression. Most patients (91.4%) improved without additional treatment. No patient died or was transferred to intensive care. This study shows that regdanvimab prevented disease progression in high-risk patients with mild to moderate COVID-19 infections during Delta variant predominance.

참고문헌 (19)

  1. Miguez-Rey E, "Monoclonal antibody therapies in the management of SARS-CoV-2 infection", Expert Opin Investig Drugs, 31, pp.41~58 (2022)
  2. "COVID-19 treatment guidelines. Anti-SARS-CoV-2 monoclonal antibodies"[URL]
  3. Ryu DK, "Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant", Biochem Biophys Res Commun, 566, pp.135~140 (2021)
  4. Kim C, "A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein", Nat Commun, 12, pp.288~ (2021)
  5. Syed YY, "Regdanvimab : First Approval", Drugs, 81, pp.2133~2137 (2021)
  6. Choi Seong Jin, "Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study", Infection and Chemotherapy, 54(1), pp.91~101 (2022), 대한감염학회[DOI]
  7. Lee JY, "Effectiveness of regdanvimab treatment in high-risk COVID-19 patients to prevent progression to severe disease", Front Immunol, 12, pp.772320~ (2021)
  8. Lee S, "Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection : A propensity score-matched retrospective cohort study", Int Immunopharmacol, 106, pp.108570~ (2022)
  9. Park Susin, "Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study", Journal of Korean Medical Science, 37(13), pp.1~16 (2022), 대한의학회[DOI]
  10. Hong Sun In, "Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea", Infection and Chemotherapy, 54(1), pp.114~124 (2022), 대한감염학회[DOI]
  11. "Status and characteristics of the SARS-CoV-2 variant outbreak in the Republic of Korea in January 2021"[URL]
  12. "Regdanivmab full Korean approval. 2021"[URL]
  13. Anderson B, "Effect of monoclonal antibody treatment on clinical outcomes in ambulatory patients with coronavirus disease 2019", Open Forum Infect Dis, 8, pp.ofab315~ (2021)
  14. "COVID-19 treatment guidelines. Clinical spectrum of SARS-CoV-2infection"[URL]
  15. Streinu-Cercel A, "Efficacy and safety of regdanvimab (CT-P59): a phase 2", 3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate coronavirus disease 2019, 2019, pp.9, ofac053~
  16. Kim JY, "Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein : two randomized, placebo-controlled, phase I studies in healthy individuals and patients with mild SARS-CoV-2 infection", Clin Ther, 43, pp.1706~1727 (2021)
  17. Ryu DK, "The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2", Biochem Biophys Res Commun, 578, pp.91~96 (2021)
  18. Kim T, "Real-world efficacy of regdanvimab on clinical outcomes in patients with mild to moderate COVID-19", J Clin Med, 11, pp.1412~ (2022)
  19. Planas D, "Considerable escape of SARS-CoV-2 Omicron to antibody neutralization", Nature, 602, pp.671~675 (2022)

관련 논문AI추천

Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of KoreaBae In-Gyu, Cho Oh-Hyun, Hong Kyung-Wook, Hong Sun In, Ryu Byung-Han대한감염학회 · Infection and Chemotherapy2022 · 제54권 제1호Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study박상원, Choi Seong Jin, Lee Eunyoung대한감염학회 · Infection and Chemotherapy2022 · 제54권 제1호Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak박상원, 이은영, Lee Chan Mi대한감염학회 · Infection and Chemotherapy2022 · 제54권 제2호Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19Choi Miyoung, Choi Won Suk, Heo Jung Yeon, Huh Kyungmin, Jeong Su Jin, Joo Eun-Jeong, Kim Jimin, Kim Sun Bean, Kim Yae-Jean, Kim Youn Jeong, Korean Society of Infectious Diseases (KSID), Peck Kyong Ran, Seo Yu Bin, Yeom Joon Sup, Yoon Young Kyung, Yu Su-Yeon대한감염학회 · Infection and Chemotherapy2021 · 제53권 제2호Clinical Effectiveness of REGN-COV2 in Patients with COVID-19 in Japan: A Retrospective Cohort Study with a Bayesian InferenceAmano Norihiko, Iwata Kentaro, Iwata Sachiyo대한감염학회 · Infection and Chemotherapy2021 · 제53권 제4호Effectiveness of Molnupiravir Treatment in Patients with COVID-19 in Korea: A Propensity Score Matched StudyBae Soon Jong, Kim Jong Mu, Kim Jungyeon, Lee Hyungmin, Park Hye Rim, Yoo Min-Gyu대한감염학회 · Infection and Chemotherapy2023 · 제55권 제4호

이 간행물의 다른 논문 (19건)

Current Status and Prospect of Qualitative Assessment of Antibiotics PrescriptionsLee Raeseok, Kim Yong Chan, Kim Hong Bin, Moon Song Mi, Kim Bongyoung, Park Se Yoonpp. 599-609Clinical Utility of Procalcitonin on Antibiotic Stewardship: A Narrative Review김종훈pp. 610-620Implementation of Procalcitonin in Antibiotic Stewardship: Derivation of a Consensus Algorithm for Procalcitonin Use in Clinical PracticePark Dae Won, Kim Hong Bin, Kim Chung-Jong, Lee Dong-Gun, Kim Jong Hun, 최준용pp. 621-636Core Elements for Implementing Antimicrobial Stewardship Programs in Korean General HospitalsKim Hong Bin, Moon Chisook, Kim Bongyoung, Kwon Ki Tae, 정혜숙, Hwang In Sun, Park Choon-Seon, Shin Ji-Yeon, 이미숙, 김신우, 박경화, 윤영경, 이혁민, Eun Byung Wook, Jeong Su Jin, Kim Hyung-Sook, Kim Yong Chanpp. 637-673Current Status of Antibiotic Stewardship and the Role of Biomarkers in Antibiotic Stewardship ProgramsKim Chung-Jongpp. 674-698
원문 보기